US5063229A - Imidazolo [1,2-a]pyrimidines and medical use thereof - Google Patents
Imidazolo [1,2-a]pyrimidines and medical use thereof Download PDFInfo
- Publication number
- US5063229A US5063229A US07/435,078 US43507889A US5063229A US 5063229 A US5063229 A US 5063229A US 43507889 A US43507889 A US 43507889A US 5063229 A US5063229 A US 5063229A
- Authority
- US
- United States
- Prior art keywords
- sub
- ethyl
- bromo
- pyrimidin
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/84—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Definitions
- novel compounds of the invention are selected from the group consisting of a compound of the formula ##STR2## wherein R 1 is selected from the group consisting of ##STR3## and --C.tbd.C--R', R is selected from the group consisting of hydrogen and alkyl of 1 to 5 carbon atoms, R' is selected from the group consisting of hydrogen, alkyl and hydroxyalkyl of 1 to 5 carbon atoms, and aryl of 6 to 10 carbon atoms optionally substituted with at least one member of the group consisting of halogen, --OH, --COOH, CF 3 and alkyl and alkoxy of 1 to 5 carbon atoms, a) A is alkyl of 1 to 5 carbon atoms, B and G together with the carbon atom to which they are attached are carbonyl or thiocarbonyl and D is selected from the group consisting of alkyl of 1 to 5 carbon atoms and phenyl optionally substituted with at least one member of the group consisting of halogen, --
- alkyl and alkoxy of 1 to 5 carbon atoms are methyl, ethyl, isopropyl, n-propyl and linear and branched butyl and pentyl, methoxy, ethoxy, isopropoxy, n-propoxy and linear and branched butoxy and pentyloxy.
- hydroxyalkyl of 1 to 5 carbon atoms are hydroxymethyl, hydroxyethyl, hydroxy-n-propyl, hydroxyisopropyl and linear or branched hydroxybutyl and hydroxypentyl.
- Examples of aryl of 6 to 10 carbon atoms are phenyl and naphthyl optionally substituted as discussed above.
- Examples of alkylthio of 1 to 5 alkyl carbon atoms are methylthio, ethylthio, n-propylthio, isopropylthio and linear and branched butylthio and pentylthio.
- alkylsulfinyl and alkylsulfonyl of 1 to 5 alkyl carbon atoms are methylsulfinyl, ethylsulfinyl, n-propylsulfinyl, isopropylsulfinyl, linear and branched butylsulfinyl and pentylsulfinyl, methylsulfonyl, ethylsulfonyl, isopropylsulfonyl, n-propylsulfonyl and linear and branched butylsulfonyl and pentylsulfonyl.
- suitable acids for the formation of the non-toxic, pharmaceutically acceptable acid addition salts are inorganic acids such as hydrochloric acid, hydrobromic acid, hydriodic acid, nitric acid, sulfuric acid and phosphoric acid and organic acids such as propionic acid, formic acid, benzoic acid, maleic acid, fumaric acid, succinic acid, tartaric acid, citric acid, oxalic acid, glyoxylyic acid, aspartic acid, alkanesulfonic acids such as methanesulfonic acid, and arylsulfonic acid such as benzenesulfonic acid.
- inorganic acids such as hydrochloric acid, hydrobromic acid, hydriodic acid, nitric acid, sulfuric acid and phosphoric acid
- organic acids such as propionic acid, formic acid, benzoic acid, maleic acid, fumaric acid, succinic acid, tartaric acid, citric acid, oxalic acid, glyoxyly
- Examples of preferred compounds of formula I are those wherein R 1 is ##STR9## and E is halogen, those wherein R 1 is --C.tbd.C--R' and E is halogen, those wherein A and B together are a bond, G and D together are ##STR10## E is halogen, X a is methoxy or methylthio and Y a and Y a ' are individually hydrogen, methyl or ethyl and E is halogen and those wherein A and B together are a bond, G is alkylthio of 1 to 5 carbon atoms and D is optionally substituted phenyl and their non-toxic, pharmaceutically acceptable acid addition salts.
- the novel process of the invention for the preparation of compounds of formula I wherein E is hydrogen comprises oxidizing a compound of the formula ##STR11## wherein B,G,D,A and R 1 are defined as above with an oxidizing agent such as manganese dioxide and optionally salifying the corresponding compound of formula I.
- the oxidation is preferably effected in an organic solvent such as chloroform at reflux.
- the compounds of formula IV may be prepared by reacting a compound of the formula ##STR12## wherein A, B, G and D have the above definitions with a source of R 1 - carbonions such as Grignard reagent of the formula R 1 MgBr III or an alkyllithium of the formula R 1 -Li III A wherein R 1 has the above definition preferably in an inert organic solvent such as tetrahydrofuran.
- a source of R 1 - carbonions such as Grignard reagent of the formula R 1 MgBr III or an alkyllithium of the formula R 1 -Li III A wherein R 1 has the above definition preferably in an inert organic solvent such as tetrahydrofuran.
- a process for the preparation of a compound of the formula ##STR17## wherein R 1 , D and E are defined as above, Alk is alkyl of 1 to 5 carbon atoms and n is 1 or 2 comprises oxidizing a compound of the formula ##STR18## wherein D, E, R 1 and Alk have the above definition and n' is 0 or 1 with an oxidizing agent such as sodium metaperiodate to obtain the compound of formula I D which may be optionally salified.
- the reaction is preferably effected in a suitable organic solvent such as aqueous alkanol such as methanol and at a suitable temperature such as about 50° C.
- the compounds of formula I C wherein n' is 0 are reacted with one equivalent of oxidizing agent.
- the alkylsulfonyl compounds of formula I D wherein n is 2 may be prepared by oxidizing the compound of formula I C wherein n' is 0 with at least two equivalents of oxidizing agent or oxidize the compound of formula I C wherein n' is 1 with at least one equivalent of oxidizing agent.
- a process for the preparation of the compounds of formula I wherein at least one of R 1 and D contains a hydroxy group comprises removing a protective group from a compound of the formula ##STR19## wherein A, B, G and E have the above definitions, D" is D or a precursor of a group D with a protected hydroxy and R" 1 is R 1 or a precursor of a group R 1 with a protected hydroxy, with the proviso that at least one of D" and R" 1 is a precursor of a group containing a protected hydroxy.
- the compounds of formula V may be prepared by one of the previous processes using starting materials wherein R 1 and/or D contains protected hydroxy groups.
- R' is hydroxyalkyl of 1 to 5 carbon atoms
- the protecting group used will conveniently be of the type customarily employed for the protection of aliphatic hydroxy groups such as tetrahydropyranyl, although other suitable protecting groups will be apparent to those skilled in the art.
- a compound of formula III or III A wherein R' or R 1 is a suitably protected hydroxyalkyl of 1 to 5 carbon atoms will be taken and reacted with the appropriate compound of formula II.
- the protected derivative of formula IV thereby obtained may then be elaborated as appropriate according to one or more of processes (A) to (C) above, the protecting group on the hydroxy substituent being retained for the remaining steps of the synthetic sequence, its removal consituting the final step thereof.
- Such a process is described in Examples 22 and 23.
- the protecting group used will conveniently be of the type customarily employed for the protection of aromatic hydroxys, a typical example being benzyl although as before other suitable protecting groups will be apparent to those skilled in the art.
- the protected derivative of formula IV involved as an intermediate in the synthetic sequence may be elaborated as appropriate according to one or more of processes (A) to (C) above. As before, the protecting group on the hydroxy will be retained for the remaining steps of the synthetic sequence and its removal will constitute the final step thereof and such a process is described in Example 14.
- novel anti-inflammatory compositions of the invention are comprised of an anti-inflammatorily effective amount of at least one compound of formula I and their non-toxic, pharmaceutically acceptable acid addition salts and an inert pharmaceutical carrier or excipient.
- the compositions may be in the form of tablets, dragees, capsules, powders, suppositories, aerosols and injectable solutions or suspensions.
- excipients examples include talc, gum arabic, lactose, starch, magnesium stearate, cocoa butter, aqueous or nonaqueous vehicles, animal or vegetable fats, paraffin derivatives, glycols, various wetting, dispersing or emulsifying agents and/or preservatives.
- compositions of the invention possess very interesting pharmacological properties; particularly they have been found to possess an anti-inflammatory effect, notably in their ability to moderate inflammatory/immune cell function by restricting arachidonic acid release and consequential eicosanoid biosynthesis. They are useful for the treatment of inflammatory and immunological disorders such as rheumatoid arthritis, osteoarthritis and psoriasis.
- the preferred active ingredients are as indicated above.
- the novel method of the invention for treating inflammation in warm-blooded animals, including humans comprises ad ministering to warm-blooded animals an anti-inflammatorily effective amount of at least one compound of formula I and their non-toxic, pharmaceutically acceptable acid addition salts.
- the compounds may be administered orally, rectally or parenterally and the usual daily dose is 0.001 to 2.5 mg/kg depending on the conditions treated, the specific compound and the method of administration.
- Imidazole-4-carboxaldehydes of formula II may be prepared by a modification of the procedures described in Helv. Chim. Acta. 1960, Vol. 43, p. 1787 and Tetrahedron, 1963, Vol. 19, p. 1883. An example of such a preparation is given below as Preparation A.
- Imidazo[1,2-a]pyrimidine-2-carboxaldehydes of formula II may be prepared as in British Patent Application No. 2,128,989 or by methods analogous thereto, as also may compounds of formula I A wherein A' and B' together are a bond, G' and D' together are ##STR20## wherein X, Y and Y' are as defined above and ##STR21## in which R is as defined above which, while not themselves being compounds of the invention, are nevertheless useful intermediates for the compounds of formula I B .
- An example of such a preparation is described in Preparation H below.
- Imidazol[1,2-a]pyridine-2-carboxaldehydes of formula II may conveniently be prepared using a variant of the process described in British Patent Application No. 2,128,989 from the corresponding imidazo[1,2-a]pyridine-2-carboxylate esters which, in turn, may themselves be obtained by the method detailed in J. Org. Chem., 1965, Vol. 30, p. 2403.
- Compounds B to E were prepared analogously.
- Compound F was prepared as described in published British Patent Application No. 2,128,989, and compound G was prepared by an analogous method.
- Compounds J and K were prepared as indicated in Example 1 Step A.
- the Yield, melting point and analytical data of starting compounds of formula II are given in Tables A and B.
- Yield, melting point and analytical data of intermediates of formula I A are given in Table C.
- the residual oil was purified by flash chromatography over 25 mg of silica, (dichloromethane: ethyl acetate 1:0 gradually changing to 0.1) to obtain 1.17 g (84%) of the 2-methyl-2-propen-1-ol as colorless crystals melting at 116°-8° C. .sup. ⁇ Max .sup.(KBr) 3160, 2960, 2920, 2870 and 1610 cm -1
- STEP B 1-(3-bromo-6-ethyl-5-methyl-7-methylthioimidazo[1,2-a]pyrimidin-2-yl)-2-methyl-2-propen-1-one
- Example 2 (3-bromo 6-ethyl 7-methoxy 5-methylimidazo [1,2-a] pyrimidin-2-yl) isopropenyl methanone.
- Example 3 (3-chloro 6-ethyl 7-methoxy 5-methylimidazo [1,2-a] pyrimidin-2-yl) isopropenyl methanone.
- Example 4 (7-methoxy 5-methylimidazo [1,2-a] pyrimidin-2-yl) ethenyl methanone.
- Example 5 (3-bromo 6-ethyl 7-methoxy 5-methylimidazo [1,2-a] pyrimidin-2-yl) ethenyl methanone.
- Example 7 [1-(4-ethylphenyl) 5-bromo 2-thiomethylimidazol-4-yl] isopropenyl methanone.
- Example 8 [1-(4-methoxyphenyl) 5-bromo 2-thiomethylimidazol-4-yl] isopropenyl methanone.
- Example 10 [1-(4-methylphenyl) 5-bromo 2-thiomethylimidazol-4-yl] isopropenyl methanone.
- Example 11 [1-(4-methylphenyl) 5-bromo 2-thioisopropylimidazol-4-yl] isopropenyl methanone.
- Example 12 [1-(4-fluorophenyl) 5-bromo 2-thiomethylimidazol-4-yl] isopropenyl methanone.
- Example 13 [1-(4-methoxyphenyl) 5-bromo 2-thiomethylimidazol-4-yl] ethenyl methanone.
- Step B The product of Step B was reacted by the method of Step B of Example 1 to obtain [1-(4-benzyloxyphenyl)-5-bromo-2-methylthioimidazol-4-yl]-2-methyl-2-propen-1-one.
- Example 18 (6-ethyl 7-methoxy 5-methylimidazo [1,2-a] pyrimidin-2-yl) phenylethynyl methanone.
- Example 19 1-(6-ethyl 7-methoxy 5-methylimidazo [1,2-a] pyrimidin-2-yl) (3,3-dimethylbut-1-ynyl) methanone.
- Example 20 (3-bromo 6-ethyl 7-methoxy 5-methylimidazo [1,2-a] pyrimidin-2-yl) (3,3-dimethylbut-1-ynyl) methanone.
- Example 21 (3-bromo 6-ethyl 7-methoxy 5-methylimidazo [1,2-a] pyrimidin-2-yl) (2-phenylethy-1-yl) methanone.
- STEP B 1-(3-bromo-6-ethyl-7-methoxy-5-methylimidazo[1,2-a]pyrimidin-2-yl)-4-(tetrahydropyran-2-yloxy)-2-butyn-1-one
- Step A The compound of Step A was reacted by the procedure of Step B of Example 1 to obtain 1-3-(bromo-6-ethyl-7-methoxy-5-methylmidazo[1,2-a]pyrimidin-2-yl)-4-(tetrahydropyran-2-yloxy)-2-butyn-1-one.
- Example 24 (3-bromo 6-ethyl 7-methoxy 5-methylimidazo [1,2-a] pyrimidin-2-yl) (propyn-1-ynyl) methanone.
- Example 25 (3-bromoimidazo [1,2-a] pyridin-2-yl) isopropenyl methanone (chlorhydrate).
- Example 26 (imidazo [1,2-a] pyridin-2-yl) isopropenyl methanone.
- Example 27 (imidazo [1,2-a] pyridin-2-yl) (2-phenylethyn-1-yl) methanone.
- Example 28 3-bromoimidazo [1,2-a] pyridin-2-yl (2-phenylethyn-1-yl) methanone.
- Tablets containing 20 mg of the compound of Example 1 or 7 and sufficient excipient of lactose, starch, talc and magnesium stearate for a final tablet weight of 100 mg were prepared.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
A compound selected from the group consisting of a compound of the formula ##STR1## and its non-toxic, pharmaceutically acceptable acid addition salts having anti-inflammatory activity and their preparation.
Description
The application is a division of U.S. patent application Ser. No. 271,732 filed Nov. 15, 1988, now U.S. Pat. No. 4,895,866 which is a division of U.S. patent application Ser. No. 080,407 filed July 31, 1987 now U.S. Pat. No. 4,810,828.
It is an object of the invention to provide the novel compounds of formula I and their non-toxic, pharmaceutically acceptable acid addition salts and their preparation.
It is another object of the invention to provide novel anti-inflammatory compositions and a novel method of treating inflammation in warm-blooded animals.
These and other objects and advantages of the invention will become obvious from the following detailed description.
The novel compounds of the invention are selected from the group consisting of a compound of the formula ##STR2## wherein R1 is selected from the group consisting of ##STR3## and --C.tbd.C--R', R is selected from the group consisting of hydrogen and alkyl of 1 to 5 carbon atoms, R' is selected from the group consisting of hydrogen, alkyl and hydroxyalkyl of 1 to 5 carbon atoms, and aryl of 6 to 10 carbon atoms optionally substituted with at least one member of the group consisting of halogen, --OH, --COOH, CF3 and alkyl and alkoxy of 1 to 5 carbon atoms, a) A is alkyl of 1 to 5 carbon atoms, B and G together with the carbon atom to which they are attached are carbonyl or thiocarbonyl and D is selected from the group consisting of alkyl of 1 to 5 carbon atoms and phenyl optionally substituted with at least one member of the group consisting of halogen, --OH, --COOH, --CF3 and alkyl and alkoxy of 1 to 5 carbon atoms or b) A and B together form a bond, G is selected from the group consisting of alkyl, alkoxy and alkylthio of 1 to 5 carbon atoms and alkylsulfinyl and alkylsulfonyl of 1 to 5 carbon atoms and D is selected from the group consisting of alkyl of 1 to 5 carbon atoms and phenyl optionally substituted with at least one member of the group consisting of halogen, --OH, --COOH, --CF3 and alkyl and alkoxy of 1 to 5 carbon atoms or c) A and B together form a bond, G and D together form a member of the group consisting of ##STR4## wherein X is alkoxy or alkylthio of 1 to 5 carbon atoms, Y and Y' are individually hydrogen or alkyl of 1 to 5 carbon atoms and E is hydrogen or halogen with the proviso when A and B are a bond and G and D together are ##STR5## and R1 is ##STR6## E is other than hydrogen and its non-toxic, pharmaceutically acceptable acid addition salts,
When A and B together form a bond and G and D together form ##STR7## the compounds of formula I may have the formula ##STR8## respectively.
Examples of alkyl and alkoxy of 1 to 5 carbon atoms are methyl, ethyl, isopropyl, n-propyl and linear and branched butyl and pentyl, methoxy, ethoxy, isopropoxy, n-propoxy and linear and branched butoxy and pentyloxy. Examples of hydroxyalkyl of 1 to 5 carbon atoms are hydroxymethyl, hydroxyethyl, hydroxy-n-propyl, hydroxyisopropyl and linear or branched hydroxybutyl and hydroxypentyl.
Examples of aryl of 6 to 10 carbon atoms are phenyl and naphthyl optionally substituted as discussed above. Examples of alkylthio of 1 to 5 alkyl carbon atoms are methylthio, ethylthio, n-propylthio, isopropylthio and linear and branched butylthio and pentylthio. Examples of alkylsulfinyl and alkylsulfonyl of 1 to 5 alkyl carbon atoms are methylsulfinyl, ethylsulfinyl, n-propylsulfinyl, isopropylsulfinyl, linear and branched butylsulfinyl and pentylsulfinyl, methylsulfonyl, ethylsulfonyl, isopropylsulfonyl, n-propylsulfonyl and linear and branched butylsulfonyl and pentylsulfonyl.
Examples of suitable acids for the formation of the non-toxic, pharmaceutically acceptable acid addition salts are inorganic acids such as hydrochloric acid, hydrobromic acid, hydriodic acid, nitric acid, sulfuric acid and phosphoric acid and organic acids such as propionic acid, formic acid, benzoic acid, maleic acid, fumaric acid, succinic acid, tartaric acid, citric acid, oxalic acid, glyoxylyic acid, aspartic acid, alkanesulfonic acids such as methanesulfonic acid, and arylsulfonic acid such as benzenesulfonic acid.
Examples of preferred compounds of formula I are those wherein R1 is ##STR9## and E is halogen, those wherein R1 is --C.tbd.C--R' and E is halogen, those wherein A and B together are a bond, G and D together are ##STR10## E is halogen, Xa is methoxy or methylthio and Ya and Ya ' are individually hydrogen, methyl or ethyl and E is halogen and those wherein A and B together are a bond, G is alkylthio of 1 to 5 carbon atoms and D is optionally substituted phenyl and their non-toxic, pharmaceutically acceptable acid addition salts.
Among the preferred compounds of formula I are
1-(3-bromo-6-ethyl-5-methyl-7-methylthioimidazo[1,2-a]-pyrimidin-2-yl)-2-methyl-2-propen-1-one;
1-[5-bromo-1-(4-ethylphenyl)-2-methylthioimidazol-4-yl]-2-methyl-2-propen-1-one;
1-[5-bromo-1-(4-methoxyphenyl)-2-methylthioimidazol-4-yl]-2-propen-1-one;
1-(3-bromo-6-ethyl-7-methoxy-5-methylimidazo[1,2-a]-pyrimidin-2-yl-2-propen-1-one;
1-(3-bromo-6-ethyl-7-methoxy-5-methylimidazol[1,2-a]-pyrimidin-2-yl)-3-phenyl-2-propyn-1-one and their non-toxic, pharmaceutically acceptable acid addition salts.
The novel process of the invention for the preparation of compounds of formula I wherein E is hydrogen comprises oxidizing a compound of the formula ##STR11## wherein B,G,D,A and R1 are defined as above with an oxidizing agent such as manganese dioxide and optionally salifying the corresponding compound of formula I. The oxidation is preferably effected in an organic solvent such as chloroform at reflux.
The compounds of formula IV may be prepared by reacting a compound of the formula ##STR12## wherein A, B, G and D have the above definitions with a source of R1 - carbonions such as Grignard reagent of the formula R1 MgBr III or an alkyllithium of the formula R1 -Li IIIA wherein R1 has the above definition preferably in an inert organic solvent such as tetrahydrofuran.
A process for the preparation of compounds of formula IB wherein E is halogen ##STR13## wherein Hal represents a halogen atom, R1 ' is ##STR14## or --C.tbd.C--R' wherein R and R' have the above definitions and a) A' is alkyl of 1 to 5 carbon atoms, B' and G' together with the carbon atom to which they are attached are carbonyl or thiocarbonyl and D' is alkyl of 1 to 5 carbon atoms or phenyl optionally substituted with at least one member of the group consisting of halogen, --OH, --COOH, --CF3 and alkyl and alkoxy of 1 to 5 carbon atoms or b) A' and B' together form a bond, G' is alkyl or alkylthio of 1 to 5 carbon atoms and D' is alkyl of 1 to 5 carbon atoms or phenyl optionally substituted with at least one member of the group consisting of halogen, --OH, --COOH, CF3 and alkyl and alkoxy of 1 to 5 carbon atoms or c) A' and B' are a bond, G' and D' together are ##STR15## wherein X, Y and Y' are as defined above comprises reacting a compound of the formula ##STR16## wherein A', B', G', D' and R'1 are defined as above with a N-halosuccinimide optionally followed by salification of the compound of formula IB. The reaction is preferably effected in an organic solvent such as chloroform or carbon tetrachloride.
A process for the preparation of a compound of the formula ##STR17## wherein R1, D and E are defined as above, Alk is alkyl of 1 to 5 carbon atoms and n is 1 or 2 comprises oxidizing a compound of the formula ##STR18## wherein D, E, R1 and Alk have the above definition and n' is 0 or 1 with an oxidizing agent such as sodium metaperiodate to obtain the compound of formula ID which may be optionally salified. The reaction is preferably effected in a suitable organic solvent such as aqueous alkanol such as methanol and at a suitable temperature such as about 50° C.
To prepare the alkylsulfinyl derivatives, the compounds of formula IC wherein n' is 0 are reacted with one equivalent of oxidizing agent. The alkylsulfonyl compounds of formula ID wherein n is 2 may be prepared by oxidizing the compound of formula IC wherein n' is 0 with at least two equivalents of oxidizing agent or oxidize the compound of formula IC wherein n' is 1 with at least one equivalent of oxidizing agent.
A process for the preparation of the compounds of formula I wherein at least one of R1 and D contains a hydroxy group comprises removing a protective group from a compound of the formula ##STR19## wherein A, B, G and E have the above definitions, D" is D or a precursor of a group D with a protected hydroxy and R"1 is R1 or a precursor of a group R1 with a protected hydroxy, with the proviso that at least one of D" and R"1 is a precursor of a group containing a protected hydroxy. The compounds of formula V may be prepared by one of the previous processes using starting materials wherein R1 and/or D contains protected hydroxy groups.
As will be appreciated from the above, certain of the compounds of the invention possess free hydroxy groups, and it may thus be necessary or desirable to protect any free hydroxy groups, during the preparation of the said compounds. In such situations, the protecting group will remain in place throughout the duration of the process sequence, and will itself be removed by traditional methods (e.g. by hydrolysis) as the final step thereof.
For example, if R' is hydroxyalkyl of 1 to 5 carbon atoms, the protecting group used will conveniently be of the type customarily employed for the protection of aliphatic hydroxy groups such as tetrahydropyranyl, although other suitable protecting groups will be apparent to those skilled in the art. Thus, a compound of formula III or IIIA wherein R' or R1 is a suitably protected hydroxyalkyl of 1 to 5 carbon atoms will be taken and reacted with the appropriate compound of formula II. The protected derivative of formula IV thereby obtained may then be elaborated as appropriate according to one or more of processes (A) to (C) above, the protecting group on the hydroxy substituent being retained for the remaining steps of the synthetic sequence, its removal consituting the final step thereof. Such a process is described in Examples 22 and 23.
Similarly, in those cases wherein R' is hydroxy-substituted aryl of 6 to 10 carbon atoms and/or D is a hydroxy-substituted phenyl, the protecting group used will conveniently be of the type customarily employed for the protection of aromatic hydroxys, a typical example being benzyl although as before other suitable protecting groups will be apparent to those skilled in the art. Again, the protected derivative of formula IV involved as an intermediate in the synthetic sequence may be elaborated as appropriate according to one or more of processes (A) to (C) above. As before, the protecting group on the hydroxy will be retained for the remaining steps of the synthetic sequence and its removal will constitute the final step thereof and such a process is described in Example 14.
The compounds are basic in character and their acid addition salts may be obtained by reacting approximately stoichiometric amounts of the compound of formula I and the appropriate acid in a suitable solvent with or without isolation of the compound of formula I
The novel anti-inflammatory compositions of the invention are comprised of an anti-inflammatorily effective amount of at least one compound of formula I and their non-toxic, pharmaceutically acceptable acid addition salts and an inert pharmaceutical carrier or excipient. The compositions may be in the form of tablets, dragees, capsules, powders, suppositories, aerosols and injectable solutions or suspensions.
Examples of suitable excipients are talc, gum arabic, lactose, starch, magnesium stearate, cocoa butter, aqueous or nonaqueous vehicles, animal or vegetable fats, paraffin derivatives, glycols, various wetting, dispersing or emulsifying agents and/or preservatives.
The compositions of the invention possess very interesting pharmacological properties; particularly they have been found to possess an anti-inflammatory effect, notably in their ability to moderate inflammatory/immune cell function by restricting arachidonic acid release and consequential eicosanoid biosynthesis. They are useful for the treatment of inflammatory and immunological disorders such as rheumatoid arthritis, osteoarthritis and psoriasis. The preferred active ingredients are as indicated above.
The novel method of the invention for treating inflammation in warm-blooded animals, including humans, comprises ad ministering to warm-blooded animals an anti-inflammatorily effective amount of at least one compound of formula I and their non-toxic, pharmaceutically acceptable acid addition salts. The compounds may be administered orally, rectally or parenterally and the usual daily dose is 0.001 to 2.5 mg/kg depending on the conditions treated, the specific compound and the method of administration.
Imidazole-4-carboxaldehydes of formula II may be prepared by a modification of the procedures described in Helv. Chim. Acta. 1960, Vol. 43, p. 1787 and Tetrahedron, 1963, Vol. 19, p. 1883. An example of such a preparation is given below as Preparation A.
Imidazo[1,2-a]pyrimidine-2-carboxaldehydes of formula II may be prepared as in British Patent Application No. 2,128,989 or by methods analogous thereto, as also may compounds of formula IA wherein A' and B' together are a bond, G' and D' together are ##STR20## wherein X, Y and Y' are as defined above and ##STR21## in which R is as defined above which, while not themselves being compounds of the invention, are nevertheless useful intermediates for the compounds of formula IB. An example of such a preparation is described in Preparation H below.
Imidazol[1,2-a]pyridine-2-carboxaldehydes of formula II may conveniently be prepared using a variant of the process described in British Patent Application No. 2,128,989 from the corresponding imidazo[1,2-a]pyridine-2-carboxylate esters which, in turn, may themselves be obtained by the method detailed in J. Org. Chem., 1965, Vol. 30, p. 2403.
In the following examples there are described several preferred embodiments to illustrate the invention. However, it is to be understood that the invention is not intended to be limited to the specific embodiments.
Step (a):
A mixture of 18 g of glucose, 12.3 of p-methoxyaniline, 36 ml of water and 1 ml of acetic acid was heated on a steam-bath for 15 minutes after which time a clear solution was formed. 7.6 g of ammonium isothiocyanate and 6 g of acetic acid were added and the solution was heated on a steam-bath for 2 hours after which time solidification occurred. The solid was digested with hot water, filtered, stirred in methanol for 1 hour, filtered, washed with ether and dried to obtain 10.5 g (32%) of intermediate (1) melting at 215°-6° C. (Tetrahedron, 1963, Vol. 19, page 1883, m.p. 215°-6° C.)
Step (b):
A mixture of 10.5 g of intermediate (1) 5.0 g of iodomethane and 5.0 g of potassium carbonate was stirred in 50 ml of dimethylformamide for 1 hour and then was diluted with water to crystallize 7.6 g (69%) of intermediate (2) as a brown solid which was used directly in the next step.
Step (c):
A mixture of 7.6 g of intermediate (2) and 16.0 g of sodium metaperiodate was stirred in 100 ml of aqueous methanol of 10% for 1 hour. The solution was concentrated under reduced pressure and diluted with water to crystallize 2.7 g of aldehyde (3) (49% yield) as colorless crystals after crystallization from ethanol melting at 118°-20° C.
Compounds B to E were prepared analogously. Compound F was prepared as described in published British Patent Application No. 2,128,989, and compound G was prepared by an analogous method. Compounds J and K were prepared as indicated in Example 1 Step A. The Yield, melting point and analytical data of starting compounds of formula II are given in Tables A and B. Yield, melting point and analytical data of intermediates of formula IA are given in Table C.
STEP A: 1-(6-ethyl-5-methyl-7-methylthioimidazo[1,2-a]pyrimidin-2-yl)-2-methyl-2-propen-1-one
(Method A)
1.2 g (4.78 mmol) of 6-ethyl-5-methyl-7-methylthioimidazo[1,2-a]pyrimidine-2-carboxaldehyde were added to a solution of 7.17 mmol of 2-propenyl magnesium bromide in 50 ml of dry tetrahydrofuran under nitrogen and the mixture was stirred at room temperature for 3 hours. The reaction mixture was quenched with aqueous ammonium chloride and was extracted with chloroform (3×50 ml). The organic layer was dried over MgSO4 and the solvent was removed under reduced pressure. The residual oil was purified by flash chromatography over 25 mg of silica, (dichloromethane: ethyl acetate 1:0 gradually changing to 0.1) to obtain 1.17 g (84%) of the 2-methyl-2-propen-1-ol as colorless crystals melting at 116°-8° C. .sup.ν Max .sup.(KBr) 3160, 2960, 2920, 2870 and 1610 cm-1
A solution of 1.4 g (4.78 mmol) of 2-methyl-2-propen-1-ol in 200 ml of chloroform was heated under reflux with 5 g of manganese dioxide for 2 hours and then was filtered hot through celite. The solvent was removed under reduced pressure to obtain 1.25 g (90%) of 1-(6-ethyl-5-methyl-7-methylthioimidazo[1,2-a]pyrimidin-2-yl)-2-methyl-2-propen-1-one as yellow crystals melting at 136°-7° C. (from ethyl acetate).
STEP B: 1-(3-bromo-6-ethyl-5-methyl-7-methylthioimidazo[1,2-a]pyrimidin-2-yl)-2-methyl-2-propen-1-one
Method B:
A solution of 1.0 g (3.63 mmol) of 1-(6-ethyl-5-methyl-7-methylthioimidazo[1,2-a]pyrimidin-2-yl)-2-methyl-2-propen-1-one in 50 ml of chloroform was treated with 0.71 g (4.0 mmol) of N-bromo succinimide. After 20 minutes at room temperature, the solvent was removed under reduced pressure and the residue was purified by flash chromatography (silica, 25 g: dichloromethane) to obtain 1.1 g (87%) of 1-(3-bromo-6-ethyl-5-methyl-7-methylthioimidazo[1,2-a]pyrimidin-2-yl)-2-methyl-2-propen-1-one in the form of pale yellow crystals melting at 87°-9° C.
Using the procedure of Step A and/or Step B of Example 1, the compounds of Examples 2 to 13 were prepared.
Example 2: (3-bromo 6-ethyl 7-methoxy 5-methylimidazo [1,2-a] pyrimidin-2-yl) isopropenyl methanone.
Example 3: (3-chloro 6-ethyl 7-methoxy 5-methylimidazo [1,2-a] pyrimidin-2-yl) isopropenyl methanone.
Example 4: (7-methoxy 5-methylimidazo [1,2-a] pyrimidin-2-yl) ethenyl methanone.
Example 5: (3-bromo 6-ethyl 7-methoxy 5-methylimidazo [1,2-a] pyrimidin-2-yl) ethenyl methanone.
Example 6: [1-(4-ethylphenyl) 2-imidazol-4-yl] isopropenyl methanone.
Example 7: [1-(4-ethylphenyl) 5-bromo 2-thiomethylimidazol-4-yl] isopropenyl methanone.
Example 8: [1-(4-methoxyphenyl) 5-bromo 2-thiomethylimidazol-4-yl] isopropenyl methanone.
Example 9: [1-(4-methoxyphenyl) 5-chloro 2-thiomethylimidazol-4-yl] isopropenyl methanone.
Example 10: [1-(4-methylphenyl) 5-bromo 2-thiomethylimidazol-4-yl] isopropenyl methanone.
Example 11: [1-(4-methylphenyl) 5-bromo 2-thioisopropylimidazol-4-yl] isopropenyl methanone.
Example 12: [1-(4-fluorophenyl) 5-bromo 2-thiomethylimidazol-4-yl] isopropenyl methanone.
Example 13: [1-(4-methoxyphenyl) 5-bromo 2-thiomethylimidazol-4-yl] ethenyl methanone.
STEP A: 1-(4-benzyloxyphenyl)-2-methylthioimidazole-4-carboxaldehyde
p-benzyloxyaniline was reacted according to method of preparation A to obtain 1-(4-benzyloxyphenyl)-2-methylthioimidazole-4-carboxaldehyde
STEP B: [1-(4-benzyloxyphenyl)-2-methylthioimidazol-4-yl]2-methyl-2-propen-1-one
The compound of Step A was reacted by the method of Step A of Example 1 to obtain [1-(4-benzyloxyphenyl)-2-methylthioimidazol-4-yl]-2-methyl-2-propen-1-one
STEP C: [1-(4-benzyloxyphenyl)-5-bromo-2-methylthioimidazol-4-yl]-2-methyl-2-propen-1-one
The product of Step B was reacted by the method of Step B of Example 1 to obtain [1-(4-benzyloxyphenyl)-5-bromo-2-methylthioimidazol-4-yl]-2-methyl-2-propen-1-one.
STEP D: [5-bromo-1-(4-hydroxyphenyl)-2-methylthioimidazol-4-yl]2-methyl-2-propen-1-one
2.7 g (6.1 mmol) of [1-(4-benzyloxyphenyl)-5-bromo-2-methylthioimidazol-4-yl]-2-methyl-2-propen-1-one were heated for 24 hours at 30° C. in 25 ml of trifluoroacetatic acid. Removal of trifluoroacetic acid was effected at 30° C. under reduced pressure followed by addition of iced water to obtain an oil which was extracted with ether and purified by flash chromatography on silica (5% ethyl acetate in petroleum ether) to obtain 1.9 g (88%) of [5-bromo-1-(4-hydroxyphenyl)-2-methylthioimidazol-4-yl]2-methyl-2-propen-1-one in the form of pale yellow crystals melting at 159°-161° C.
Using the method of Example 1, the corresponding compound of formula IA was reacted to obtain the compound of Example 15.
A mixture of 3.0 g (8.6 mmol) of [5-chloro-1-(4-ethylphenyl)-2-(prop-2-ylthio)-imidazol-4-yl]-2-methyl-2-propen-1-one and 2.3 g (11 mmol) of sodium metaperiodate was heated at 50° C. for 3 hours in 30 ml of 90% aqueous methanol. The mixture was cooled and poured into water. Extraction with dichloromethane yielded an oil which was purified by flash chromatography on silica (20% ethyl acetate in petroleum ether) to obtain 1.3 g (41%) of [5-chloro-1-(4-ethylphenyl)-2-(prop-2-ylsulfinyl)-imidazol-4-yl]-2-methyl-2-propen-1-one as cream-colored crystals melting at 83°-4° C.
Using the method of Example 16, the corresponding compound of formula IC was reacted to obtain the compound of Example 17.
Using the methods of Step A or B of Example 1, the corresponding compounds of formulae II or IA respectively were reacted to obtain the compounds of Examples 18 to 21.
Example 18: (6-ethyl 7-methoxy 5-methylimidazo [1,2-a] pyrimidin-2-yl) phenylethynyl methanone.
Example 19: 1-(6-ethyl 7-methoxy 5-methylimidazo [1,2-a] pyrimidin-2-yl) (3,3-dimethylbut-1-ynyl) methanone.
Example 20: (3-bromo 6-ethyl 7-methoxy 5-methylimidazo [1,2-a] pyrimidin-2-yl) (3,3-dimethylbut-1-ynyl) methanone.
Example 21: (3-bromo 6-ethyl 7-methoxy 5-methylimidazo [1,2-a] pyrimidin-2-yl) (2-phenylethy-1-yl) methanone.
STEP A: 1-(6-ethyl-7-methoxy-5-methylimidazo[1,2-a]pyrimidin-2-yl)-4-(tetrahydropyran-2-yloxy)-2-butyn-1-one
6-ethyl-7-methoxy-5-methylimidazo[1,2-a]pyrimidin-2-carboxaldehyde and 3-(tetrahydropyran-2-yloxy)-1-propynylmagnesium bromide [J. Chem. Soc., 1950, 3646] were reacted by the method of Step A of Example 1 to obtain 1-(6-ethyl-7-methoxy-5-methylimidazol[1,2-a]pyrimidin-2-yl)-4-(tetrahydropyran-2-yloxy)-2-butyn-1-one.
STEP B: 1-(3-bromo-6-ethyl-7-methoxy-5-methylimidazo[1,2-a]pyrimidin-2-yl)-4-(tetrahydropyran-2-yloxy)-2-butyn-1-one
The compound of Step A was reacted by the procedure of Step B of Example 1 to obtain 1-3-(bromo-6-ethyl-7-methoxy-5-methylmidazo[1,2-a]pyrimidin-2-yl)-4-(tetrahydropyran-2-yloxy)-2-butyn-1-one.
STEP C: 1-(3-bromo-6-ethyl-7-methoxy-5-methylimidazo[1,2-a]pyrimidin-2-yl)-4-hydroxy-2-butyn-1-one
A solution of 5.0 g (11.5 mmol) of 1-(3-bromo-6-ethyl-7-methoxy-5-methylimidazo[1,2-a]pyrimidin-2-yl)-4-(tetrahydropyran-2-yloxy)-2-butyn-1-one in a mixture of 100 ml of methanol and 35 ml of 2N hydrochloric acid stood at room temperature for 30 minutes and then was neutralized with aqueous sodium bicarbonate. Extraction with chloroform gave an oil which was chromatographed over silica (chloroform: ether: methanol 100:0:0 gradually changing to 0:95:5) to obtain 1.3 g (32%) of 1-(3-bromo-6-ethyl-7-methoxy-5-methylimidazo [1,2-a]pyrimidin-2-yl)-4-hydroxy-2-butyn-1-one as off-white crystals melting at 212°-3° C. (decomp.).
STEP A: 1-(6-ethyl-7-methoxy-5-methylimidazo[1,2-a]pyrimidin-2-yl)-4-(tetrahydropyran-2-yloxy)-2-butyn-1-one
Using the procedure of Step A of Example 22, 1-(6-ethyl-7-methoxy-5-methylimidazo[1,2-a]pyrimidin-2-yl)-4-(tetrahydropyran-2-yloxy)-2-butyn-1-one was prepared.
STEP B: 1-(6-ethyl-7-methoxy-5-methylimidazo[1,2-a]pyrimidin-2-yl)-4-hydroxy-2-butyn-1-one
Using the method of Step C of Example 22, the compound of Step A was reacted to obtain a 1-(6-ethyl-7-methoxy-5-methylimidazol[1,2-a]pyrimidin-2-yl)-4-hydroxy-2-butyn-1-one
Using the methods of Step A or B of Example 1, the corresponding compounds of formulae II or IA respectively were reacted to obtain the compounds of Examples 24 to 28. The yield, melting point and analytical data of compounds of formula I are given in Tables 1 to 4.
Example 24: (3-bromo 6-ethyl 7-methoxy 5-methylimidazo [1,2-a] pyrimidin-2-yl) (propyn-1-ynyl) methanone.
Example 25: (3-bromoimidazo [1,2-a] pyridin-2-yl) isopropenyl methanone (chlorhydrate).
Example 26: (imidazo [1,2-a] pyridin-2-yl) isopropenyl methanone.
Example 27: (imidazo [1,2-a] pyridin-2-yl) (2-phenylethyn-1-yl) methanone.
Example 28: 3-bromoimidazo [1,2-a] pyridin-2-yl (2-phenylethyn-1-yl) methanone.
TABLE A
__________________________________________________________________________
##STR23##
Yield
IR (KBr disc)
M.p. Theory/Found (%)
PREP
G D (%) (cm.sup.-1)
(°C.)
Formula
M.W.
C H N
__________________________________________________________________________
A MeS
##STR24##
49 3130, 1690, 1670
118-20
C.sub.12 H.sub.12 N.sub.2 O.sub.2
248.3
58.05 57.65
4.87 4.88
11.28 11.09
B MeS
##STR25##
80 3130, 1668, 1650
88-90
C.sub.13 H.sub.14 N.sub.2 OS
246.3
63.39 63.44
5.73 5.73
11.37 11.41
C MeS
##STR26##
83 1680 111-3
C.sub.12 H.sub.12 N.sub.2 OS
232.3
D iPrS
##STR27##
75 1670 63-4 C.sub.14 H.sub.16 N.sub.2 OS
260.3
E MeS
##STR28##
90 1690, 1675
130-1
C.sub.11 H.sub.9 FN.sub.2 OS
236.3
__________________________________________________________________________
TABLE B
__________________________________________________________________________
##STR29##
Yield
IR (KBr disc)
M.p. Theory/Found (%)
PREP
X Y Y' (%) (cm.sup.-1)
(°C.)
Formula
M.W.
C H N S
__________________________________________________________________________
F MeO
Et
Me 72 3120, 3000, 2980,
185-6
C.sub.11 H.sub.13 N.sub.3 O.sub.2
219.2
60.26
5.98
19.17
2950, 1690, 1640 59.97
5.97
19.05
G MeS
Et
Me 85 3098, 2960, 2915,
203-4
C.sub.11 H.sub.13 N.sub.3 OS
235.3
56.15
5.58
17.85
13.63
2860, 1675, 1610 56.35
5.58
17.95
13.34
__________________________________________________________________________
TABLE C
__________________________________________________________________________
##STR30##
Yield
IR (KBr disc)
M.p. Theory/Found (%)
PREP
X Y Y' R (%) (cm.sup.-1)
(°C.)
Formula
M.W.
C H N S
__________________________________________________________________________
H MeS
Et
Me Me 76 2970, 1630, 1615
136-7
C.sub.14 H.sub.17 N.sub.3 OS
275.4
61.06
6.24
15.25
11.64
60.91
6.22
15.17
11.54
J MeO
Et
Me Me 35 3130, 1640
148-50
C.sub.14 H.sub.17 N.sub.3 O.sub.2
259.3
64.85
6.61
16.20
64.67
6.57
16.12
K MeO
H Me Me 56 3150, 2980, 2950,
151 C.sub.12 H.sub.13 N.sub.3 O.sub.2
231.25
62.32
5.68
18.16
1625 62.20
5.70
18.14
__________________________________________________________________________
TABLE 1
__________________________________________________________________________
##STR31##
IR (KBr
Meth-
Yield
disc) M.p. Theory/Found (%)
Ex
X Y Y' E R od (%) (cm.sup.-1)
(°C.)
Formula M.W.
C H N Hal S
__________________________________________________________________________
1 MeS
Et
Me Br
Me B 87 2960, 2920,
87-9
C.sub.14 H.sub.16 BrN.sub.3 OS
354.3
47.46
4.56
11.86
22.55(Br)
9.05
1640, 1600 47.32
4.56
11.82
22.54
9.02
2 MeO
Et
Me Br
Me B 87 2960, 1635,
101-2
C.sub.14 H.sub.16 BrN.sub.3 O.sub.2
338.2
49.71
4.78
12.42
23.63(Br)
1625 49.73
4.72
12.31
23.67
3 MeO
Et
Me Cl
Me B 62 2965, 1625
111-2
C.sub.14 H.sub.16 ClN.sub.3 O.sub.2
293.8
57.24
5.50
14.30
12.07(Cl)
57.03
5.49
14.25
12.17
4 MeO
H Me Br
Me B 98 3070, 2950,
145-6
C.sub.12 H.sub.12 BrN.sub.3 O.sub.2
310.15
1630 decomp
5 MeO
Et
Me Br
H B 47 2970, 2940,
120-3
C.sub.13 H.sub.14 BrN.sub.3 O.sub.2
324.2
48.16
4.36
12.96
24.65(Br)
2875, 1670,
decomp 48.05
4.32
12.73
24.45
1625
__________________________________________________________________________
TABLE 2
__________________________________________________________________________
##STR32##
IR
Ex- (KBr
am- Meth-
Yield
disc)
M.p. Theory/Found (%)
ple
G D E R od (%) (cm.sup.-1)
(°C.)
Formula M.W.
C H N S
__________________________________________________________________________
6 MeS
##STR33##
H Me A 43 3120, 1636, 1626, 1611
46-7
C.sub.16 H.sub.18 N.sub.2 OS
286.4
67.10 67.18
6.33 6.24
9.78 9.77
11.19 11.23
7 MeS
##STR34##
Br
Me B 77 1636, 1620
94-6
C.sub.16 H.sub.17 BrN.sub.2 OS
365.3
52.61 52.62
4.69 4.69
7.67 7.67
__________________________________________________________________________
Ex-
am- Meth-
Yield
IR M.p. Theory/Found (%)
ple
G D E R od (%) (cm.sup.-1)
(°C.)
Formula M.W.
C H N Other
__________________________________________________________________________
8 MeS
##STR35##
Br
CH.sub.3
B 84 1630, 1620, 1605
128-9
C.sub.15 H.sub.15 BrN.sub.2 O.sub.2
367.3
49.05 48.86
4.12 4.10
7.63 7.55
21.76(Br)
21.74
9 MeS
##STR36##
Cl
CH.sub.3
B 93 1630, 1620, 1600
110-1
C.sub.15 H.sub.15 ClN.sub.2 O.sub.2
322.8
55.81 55.12
4.68 4.74
8.68 8.53
10.98(Cl)
11.39
10 MeS
##STR37##
Br
CH.sub.3
B 52 1630, 1610
89-90
C.sub.15 H.sub.15 BrN.sub.2
351.3
51.29 51.09
4.30 4.29
7.98 7.89
22.75(Br)
22.83
11 iPrS
##STR38##
Br
CH.sub.3
B 66 1635, 1615, 1605
135-6
C.sub.17 H.sub.19 BrN.sub.2 OS
379.3
53.83 53.76
5.05 5.07
7.39 7.33
8.45(S) 8.43
12 MeS
##STR39##
Br
CH.sub.3
B 75 1635, 1595
99-101
C.sub.14 H.sub.12 BrFN.sub.2 OS
355.2
47.33 47.37
3.41 3.48
7.81 7.81
9.02(S) 9.05
13 MeS
##STR40##
Br
H B 68 1655, 1600
117-9
C.sub.14 H.sub.13 BrN.sub.2 O.sub.2
353.2
47.60 47.36
3.71 3.75
7.93 7.79
22.62(Br)
22.72
14 MeS
##STR41##
Br
CH.sub.3
B 86 3220, 1610, 1590
159-61
C.sub.14 H.sub.13 BrN.sub.2 O.sub.2
353.2
47.60 47.63
3.71 3.72
7.93 7.82
15 iPrS
Et Br
CH.sub.3
B 53 2960,
oil C.sub.12 H.sub.17 BrNO.sub.2 S
317.2
45.43
5.40
8.83
1635, 44.98
5.37
8.69
1590
16 iPrSO
##STR42##
Cl
CH.sub.3
C 41 1640, 1610, 1595
83-4
C.sub.18 H.sub.21 ClN.sub.2 O.sub.2
364.8
17 EtSO
##STR43##
Cl
CH.sub.3
C 33 1640, 1610, 1600
76-8
C.sub.17 H.sub.19 ClN.sub.2 O.sub.2
350.8
__________________________________________________________________________
TABLE 3
__________________________________________________________________________
##STR44##
Meth-
Yield M.p. Theory/Found (%)
Ex
X Y Y' E R' od (%) IR (cm.sup.-1)
(°C.)
Formula M.W.
C H N Hal
__________________________________________________________________________
18
MeO
Et
Me H Ph A 86 2197, 1630
194-6
C.sub.19 H.sub.17 N.sub.3 O.sub.2
319.4
71.46
5.37
13.16
71.33
5.42
13.11
19
MeO
Et
Me H .sub.-t-Bu
A 71 2965, 2215,
133-5
C.sub.17 H.sub.21 N.sub.3 O.sub.2
299.3
68.21
7.07
14.04
1635 68.19
7.09
14.06
20
MeO
Et
Me Br
.sub.-t-Bu
B 86 2970, 2930,
186-7
C.sub.17 H.sub.20 BrN.sub.3 O.sub.2
378.3
53.97
5.34
11.10
21.12(Br)
2870, 2200, 53.72
5.33
10.97
20.89
1640, 1620
21
MeO
Et
Me Br
Ph B 79 3050, 2960,
187-190
C.sub.19 H.sub.16 BrN.sub.3 O.sub.2
398.3
57.30
4.06
10.55
20.06(Br)
2920, 2200, 57.24
4.09
10.45
20.11
1630
22
MeO
Et
Me H CH.sub.2 OH
A 41 3400, 3125,
176-186
C.sub.14 H.sub.15 N.sub.3 O.sub.3
273.3
61.53
5.53
15.38
2210, 1635
(decomp)
23
MeO
Et
Me Br
CH.sub.2 OH
B 28 3250, 2980,
212-3
C.sub.14 H.sub.14 BrN.sub.3 O.sub.3
352.2
47.74
4.01
11.93
22.69(Br)
2880, 2220,
(decomp) 47.63
4.08
11.78
22.36
1630
24
MeO
Et
Me Br
CH.sub.3
B 93 2960, 2230,
170-2
C.sub.14 H.sub.14 BrN.sub.3 O
320.2
52.51
4.42
13.12
24.96(Br)
2205, 1630
(decomp)
__________________________________________________________________________
TABLE 4
__________________________________________________________________________
##STR45##
Meth-
Yield M.p. Theory/Found (%)
Ex
X Y Y'
E R.sub.1 od (%) IR (cm.sup.-1)
(°C.)
Formula
M.W.
C H N Hal
__________________________________________________________________________
25
H H H Br
CMeCH.sub.2
B 79 3070, 2540, 1650
140-2
C.sub.11 H.sub.9 BrN.sub.2 O
301.6
43.81
3.35
9.28
(HCl 43.57
3.41
9.11
salt)
26
H H H H CMeCH.sub.2
A 77 3145, 3100, 3080,
93-4
C.sub.11 H.sub.10 N.sub.2 O
186.2
70.95
5.42
15.04
3040, 1635 71.08
5.40
15.03
27
H H H H CCPh A 80 3140, 3100, 3080,
168 C.sub.16 H.sub.10 N.sub.2 O
246.3
78.03
4.10
11.37
3050, 2190, 1630 77.96
4.23
11.31
28
H H H Br
CCPh B 74 3080, 3050, 2200,
133-4
C.sub.16 H.sub.9 BrN.sub.2 O
325.15
59.10
2.80
8.61
24.57(Br)
1630 59.01
2.92
8.60
24.66
__________________________________________________________________________
Tablets containing 20 mg of the compound of Example 1 or 7 and sufficient excipient of lactose, starch, talc and magnesium stearate for a final tablet weight of 100 mg were prepared.
The inhibition of ionophore-stimulated release of free arachidonic acid from [14 C]-arachidonic acid pre-labelled rat peritoneal neutrophils was studied using modifications of the method of Ahnfelt-Ronne and Arrigoni-Martelli [Biochemical Pharmacol., (1982) Vol. 31, p. 2619]. The results below show the micromolar concentrations of test compound required to inhibit, by 50% compared to controls, the release of radiolabelled products into supernatant liquid (IC50 -μM).
______________________________________
Example
IC.sub.50 - μM
______________________________________
1 6.8
2 17
3 21
4 7.4
5 1.7
6 3.8
7 2.5
8 7.2
9 9.1
10 10
11 3.7
12 15
13 2.3
14 >10
15 17
16 4.4
17 --
18 12
19 16
20 4.2
21 1.5
22 59
23 46
24 7.2
25 28
26 >100
27 41
28 5.2
______________________________________
Various modifications of the compounds and methods of the invention may be made without departing from the spirit or scope thereof and it is to be understood that the invention is intended to be limited only as defined in the appended claims.
Claims (12)
1. A compound selected from the group consisting of compound of the formula ##STR46## wherein R1 is selected from the group consisting of ##STR47## and --C.tbd.C--R', R is selected from the group consisting of hydrogen and alkyl of 1 to 5 carbon atoms, R' is selected from the group consisting of hydrogen, alkyl and hydroxyalkyl of 1 to 5 carbon atoms, and aryl of 6 to 10 carbon atoms unsubstituted or substituted with at least one member of the group consisting of halogen, --OH, --COOH, --CF3 and alkyl and alkoxy of 1 to 5 carbon atoms, A and B together form a bond, G and D together form ##STR48## wherein X is alkyl or alkylthio of 1 to 5 carbon atoms, Y and Y' are individually hydrogen or alkyl of 1 to 5 carbon atoms and E is hydrogen or halogen with the proviso when A and B are a bond and G and D together are ##STR49## and R1 is ##STR50## E is other than hydrogen or a non-toxic, pharmaceutically acceptable acid addition salt.
2. A compound of claim 1 wherein E is halogen.
3. A compound of claim 1 wherein A and B taken together are a bond and G and D are ##STR51## and Xa is methoxy or methylthio and Ya and Ya ' are individually selected from the group consisting of hydrogen, methyl and ethyl and E is halogen.
4. An anti-inflammatory composition comprising an anti-inflammatorily effective amount of at least one compound of claim 1 and an inert pharmaceutical carrier.
5. A composition of claim 4 wherein E is halogen.
6. A composition of claim 4 wherein A and B taken together are a bond and G and D are ##STR52## and Xa is methoxy or methylthio and Ya and Ya ' are individually selected from the group consisting of hydrogen, methyl and ethyl and E is halogen.
7. A method of relieving inflammation in warm-blooded animals comprising administering to warm-blooded animals an anti-inflammatorily effective amount of at least one compound of claim 1.
8. A method of claim 7 wherein E is halogen.
9. A method of claim 7 wherein A and B taken together are a bond and G and D are ##STR53## and Xa is methoxy or methylthio and Ya and Ya ' are individually selected from the group consisting of hydrogen, methyl and ethyl and E is halogen.
10. A compound of claim 1 selected from the group consisting of 1-(3-bromo-6-ethyl-5-methyl-7-methylthioimidazo[1,2-a] pyrimidin-2-yl)-2-methyl-2-propen-1-one; 1-(3-bromo-6-ethyl-7-methoxy-5-methylimidazo[1,2-a] pyrimidin-2-yl)-2-propen-1-one; and 1-(3-bromo-6-ethyl-7-methxoy-5-methylimidazo[1,2-a]pyrimidin-2-yl)-3-phenyl-2-propyn-1-one and their non-toxic, pharmaceutically acceptable acid addition salts.
11. A composition of claim 4 wherein the active compound is selected from the group consisting of 1-(3-bromo-6-ethyl-5-methyl-7-methylthioimidazo[1,2-a]pyrimidin-2-yl-2methyl-2-propen-1-one; 1-(3-bromo-6-ethyl-7-methoxy-5-methylimidazo[1,2-a]pyrimidin-2-yl)-2-propen-1-one; and 1-(3-bromo-6-ethyl-7-methoxy-5-methylimidazo[1,2-a]pyrimidin-2-yl)-3-phenyl-2-propyn-1-one and their non-toxic, pharmaceutically acceptable acid addition salts.
12. A method of claim 7 wherein the active compound is selected from the group consisting of 1-(3-bromo-6-ethyl-5-methyl-7-methylthioimidazo[1,2-a]pyrimidin-2yl)-2-methyl-2-propen-1-one; 1-(3-bromo-6-ethyl-7-methoxy-5-methylimidazo[1,2-a]pyrimidin-2-yl)-2-propen-1-one; and 1-(3-bromo-6-ethyl-7-methoxy-7-methylimidazo[1,2-a]pyrimidin-2-yl)-3-phenyl-2-propyn-1-one and their non-toxic, pharmaceutically acceptable acid addition salts.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB868620060A GB8620060D0 (en) | 1986-08-18 | 1986-08-18 | Chemical compounds |
| GB8620060 | 1986-08-28 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US07/271,732 Division US4895866A (en) | 1986-08-18 | 1988-11-15 | Anti-inflammatory imidazole compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US5063229A true US5063229A (en) | 1991-11-05 |
Family
ID=10602866
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US07/080,407 Expired - Fee Related US4810828A (en) | 1986-08-18 | 1987-07-31 | Anti-inflammatory imidazole compounds |
| US07/271,732 Expired - Fee Related US4895866A (en) | 1986-08-18 | 1988-11-15 | Anti-inflammatory imidazole compounds |
| US07/435,078 Expired - Fee Related US5063229A (en) | 1986-08-18 | 1989-11-09 | Imidazolo [1,2-a]pyrimidines and medical use thereof |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US07/080,407 Expired - Fee Related US4810828A (en) | 1986-08-18 | 1987-07-31 | Anti-inflammatory imidazole compounds |
| US07/271,732 Expired - Fee Related US4895866A (en) | 1986-08-18 | 1988-11-15 | Anti-inflammatory imidazole compounds |
Country Status (5)
| Country | Link |
|---|---|
| US (3) | US4810828A (en) |
| EP (1) | EP0261004B1 (en) |
| JP (1) | JP2651912B2 (en) |
| DE (1) | DE3785987T2 (en) |
| GB (2) | GB8620060D0 (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8712466D0 (en) * | 1987-05-27 | 1987-07-01 | Roussel Lab Ltd | Chemical compounds |
| FR2638161B1 (en) * | 1988-10-24 | 1991-01-11 | Centre Nat Rech Scient | NOVEL BENZOYL-2 IMIDAZO (1,2-A) PYRIDINES AND SALTS THEREOF, PROCESS FOR THEIR PREPARATION, THEIR USE AS MEDICAMENTS AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
| JPH0441481A (en) * | 1990-06-05 | 1992-02-12 | Nippon Synthetic Chem Ind Co Ltd:The | Halogenation of imidazoles |
| DE4225629A1 (en) * | 1992-07-30 | 1994-02-03 | Degussa | Heterocyclic compounds |
| US5716958A (en) * | 1994-10-27 | 1998-02-10 | Tobishi Pharmaceutical Co., Ltd. | Amino acid derivative having anti-CCK activity |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0061380A1 (en) * | 1981-03-25 | 1982-09-29 | Synthelabo | Imidazo (1,2-a) pyrimidine derivatives, their preparation and their therapeutical use |
| EP0217142A2 (en) * | 1985-09-30 | 1987-04-08 | Yoshitomi Pharmaceutical Industries, Ltd. | A polyazaheterocyclic compound |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GR76063B (en) * | 1981-04-03 | 1984-08-03 | Roussel Uclaf | |
| ZA835684B (en) * | 1982-08-27 | 1985-03-27 | Roussel Uclaf | Imidazo(1,2-a)pyrimidines |
| IL69417A (en) * | 1982-08-27 | 1987-12-20 | Roussel Uclaf | 2-acyl imidazo(1,2-a)pyrimidines,their preparation and pharmaceutical compositions containing them |
| GB8334210D0 (en) * | 1983-12-22 | 1984-02-01 | Roussel Lab Ltd | Imidazo(1 2-c)pyrimidines |
-
1986
- 1986-08-18 GB GB868620060A patent/GB8620060D0/en active Pending
-
1987
- 1987-07-30 EP EP87401777A patent/EP0261004B1/en not_active Expired - Lifetime
- 1987-07-30 DE DE87401777T patent/DE3785987T2/en not_active Expired - Fee Related
- 1987-07-31 US US07/080,407 patent/US4810828A/en not_active Expired - Fee Related
- 1987-08-17 GB GB8719403A patent/GB2193962B/en not_active Expired - Lifetime
- 1987-08-18 JP JP62203585A patent/JP2651912B2/en not_active Expired - Lifetime
-
1988
- 1988-11-15 US US07/271,732 patent/US4895866A/en not_active Expired - Fee Related
-
1989
- 1989-11-09 US US07/435,078 patent/US5063229A/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0061380A1 (en) * | 1981-03-25 | 1982-09-29 | Synthelabo | Imidazo (1,2-a) pyrimidine derivatives, their preparation and their therapeutical use |
| EP0217142A2 (en) * | 1985-09-30 | 1987-04-08 | Yoshitomi Pharmaceutical Industries, Ltd. | A polyazaheterocyclic compound |
Also Published As
| Publication number | Publication date |
|---|---|
| EP0261004B1 (en) | 1993-05-26 |
| DE3785987T2 (en) | 1993-11-04 |
| GB8719403D0 (en) | 1987-09-23 |
| GB8620060D0 (en) | 1986-10-01 |
| US4810828A (en) | 1989-03-07 |
| JP2651912B2 (en) | 1997-09-10 |
| DE3785987D1 (en) | 1993-07-01 |
| JPS6351374A (en) | 1988-03-04 |
| EP0261004A3 (en) | 1990-10-03 |
| EP0261004A2 (en) | 1988-03-23 |
| GB2193962A (en) | 1988-02-24 |
| GB2193962B (en) | 1990-07-18 |
| US4895866A (en) | 1990-01-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU660337B2 (en) | 1,3-dihydro-2H-imidazo(4,5-B)quinolin-2-one derivatives as phosphodiesterase inhibitors | |
| US4822805A (en) | Pyridyl-imidazole compounds which have useful pharmaceutical activity | |
| US5958950A (en) | Benzimidazole compounds useful for the treatment of inflammatory disease, atherosclerosis, restenosis or inhibiting lipoxygenase | |
| DE69233113T2 (en) | Condensed heterocyclic compounds, their preparation and use | |
| US20030078276A1 (en) | Matrix metalloproteinase inhibitors | |
| US5252584A (en) | Hydroxyquinolone derivatives | |
| EP0385850A2 (en) | Benzimidazole and azabenzimidazole derivatives, process for their preparation, synthesis intermediates, pharmaceutical compositions containing them, useful for the treatment of cardiovascular diseases and duodenal ulcers | |
| HU198493B (en) | Process for producing new pyrazolo/3,4-d/pyrimidine derivatives and pharmaceutical compositions comprising same | |
| US5354759A (en) | Angiotenin II antagonizing heterocyclic compounds | |
| JP2003513977A (en) | Substituted 2-aryl-3- (heteroaryl) -imidazo [1,2-α] pyrimidines and related pharmaceutical compositions and methods | |
| SK12332003A3 (en) | Thiohydantoins and use thereof for treating diabetes | |
| US3993656A (en) | 1,8-Naphthyridine compounds | |
| SK109999A3 (en) | Compounds for inhibition of gastric acid secretion | |
| US6130333A (en) | Bicyclic imidazolyl derivatives as phosphodiesterase inhibitors, pharmaceutical compositions and method of use | |
| HU205354B (en) | Process for producing new tricyclic benzimidazoles and pharmaceutical compositions comprising same | |
| JPH0597816A (en) | 4-aryl-thiazole or imidazole derivative | |
| JPH03181469A (en) | Quinazolin-3-alkanoic acid derivative, salt and production thereof | |
| EP0276825B1 (en) | 4 (3h)-quinazolinone derivatives, processes for their preparation and pharmaceutical compositions | |
| EP0682021A1 (en) | Benzimidazoles, medicines containing them and process for their preparation | |
| FR2523582A1 (en) | SUBSTITUTED 1H-PYRAZOLO (1,5-A) PYRIMIDINES, IN PARTICULAR USE AS ANTI-INFLAMMATORY AND ANALGESIC DRUGS, AND PROCESS FOR THEIR PREPARATION | |
| US4665075A (en) | Derivatives of hydroxy- or amino-substituted (piperidinylalkyl)quinazolines | |
| US4940711A (en) | Antihypertensive N-piperazinylalkanoylanilides | |
| JPH0631221B2 (en) | Dihydropyridine anti-allergic agent | |
| US5063229A (en) | Imidazolo [1,2-a]pyrimidines and medical use thereof | |
| DE10237883A1 (en) | Substituted isoxazole derivatives and their use in pharmacy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FEPP | Fee payment procedure |
Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
| FPAY | Fee payment |
Year of fee payment: 4 |
|
| REMI | Maintenance fee reminder mailed | ||
| LAPS | Lapse for failure to pay maintenance fees | ||
| FP | Lapsed due to failure to pay maintenance fee |
Effective date: 19991105 |
|
| STCH | Information on status: patent discontinuation |
Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362 |